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There  is  tremendous  inter-individual  variation  in  the 
response  to  painful  stimuli.  A  level  of  pain  that 
completely incapacitates one individual may cause only a 
minor annoyance in another. Characterizing the genetic 
factors affecting susceptibility to chronic pain could lead 
to novel treatment or prevention strategies, which are 
desperately needed. A recent paper by Costigan et al. [1] 
presents  a  bold  step  toward  understanding  these 
differences. The authors performed a multi-dimensional 
analysis  using  rat  gene  expression  and  human  genetic 
association that identified a new genetic factor affecting 
susceptibility  to  chronic  pain.  This  study  [1]  was 
initiated by analysis of gene expression changes within 
rat dorsal root ganglia obtained after nerve damage was 
induced in three different models of chronic pain. The 
mRNA for a potassium channel alpha subunit (Kcns1) 
was  constitutively  expressed  in  sensory  neurons,  but 
was downregulated after three types of nerve injury in 
these models.
Other  studies  have  successfully  identified  a  human 
genetic susceptibility factor on the basis of a candidate 
gene  emerging  from  analysis  of  a  rodent  model  [2]. 
Costigan  and  colleagues  [1]  therefore  examined  SNP 
alleles  within  the  human  homolog  (KCNS1)  in  five 
independent cohorts (two with chronic low back pain, 
two  after  limb  amputation  and  one  after  mastectomy) 
that have a high incidence of chronic pain. In four of the 
five cohorts studied, there was a significant association of 
the Val allele at a nonsynonymous SNP (rs734784, Val/
Ile)  with  increased  risk  for  chronic  pain.  For  example, 
homozygous Val/Val individuals had a 2.4-fold increased 
relative risk of failing to achieve pain improvement 1 year 
after back surgery. The proportion of individuals without 
phantom limb pain after leg amputation was 45% in those 
without  the  Val  allele,  but  fell  to  22%  in  Val/Val 
homozygotes.  Among  healthy  volunteers  that  were 
subjected to multiple experimental pain stimuli, Val/Val 
homozygous individuals showed greater sensitivity to the 
painful stimuli [1].
Although experimental studies demonstrating an allelic 
effect  were  not  presented,  which  is  a  substantial 
limitation of this study, these results [1] make it likely 
that KCNS1 alleles contribute to susceptibility to chronic 
pain.  KCNS1  encodes  the  Kv9.1  potassium  channel 
subunit.  Although  KCNS1  by  itself  does  not  have 
potassium channel function when tested in heterologous 
expression  systems,  its  expression  has  been  shown  to 
modulate the currents formed by other channels [3-5]. 
Voltage-gated potassium channels have important effects 
on  neuronal  function,  including  altering  the  resting 
membrane potential and the shape and frequency of the 
action potential. Similarly, gain-of-function mutations in 
the Nav1.7 sodium channel cause syndromes associated 
with increased pain sensitivity [6,7].
The need for new treatments for chronic pain
Chronic pain has a huge impact on our society, and its 
treatment  is  a  major  driver  for  the  increasing  cost  of 
health care. An estimated 76 million people in the US 
have chronic pain, which costs the US public over $100 
billion  per  year.  Approximately  25%  of  chronic  pain  is 
neuropathic  (caused  by  nerve  damage),  which  is 
characterized  by  spontaneous  pain  that  is  burning  or 
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© 2010 BioMed Central Ltdstabbing  in  nature.  This  can  develop  after  limb 
amputation,  mastectomy  or  lower  back  injury,  or  in 
individuals  with  a  long  history  of  diabetes.  Although 
multiple kinds of treatment can be used, they often have 
limited efficacy, and chronic pain is often managed by 
administration  of  opioids  (morphine  and  related 
synthetic  compounds,  including  hydrocodone).  The 
increased focus on pain management resulted in a six-
fold increase in the per capita sales of prescription opioid 
medications  in  the  US  between  1997  and  2006  [8]. 
Hydrocodone-acetaminophen  is  prescribed  over  100 
million times per year in the US, which is far more than 
any  other  medication,  including  lipid-lowering  and 
blood-pressure-lowering  agents  [9].  This  has  led  to  a 
dramatic  increase  in  the  incidence  of  opioid  misuse, 
emergency room visits due to opioid analgesic poisoning, 
and fatal opioid overdose. Prescription opioids have now 
surpassed marijuana as the drug that is most commonly 
abused among the newly initiated [10].
Because of the enormity of this public health problem, 
we desperately need new approaches for the prevention 
or treatment of chronic pain conditions. It is likely that 
genetic  discoveries  can  lead  to  new  approaches  for 
chronic pain, because genetic discoveries have catalyzed 
new  approaches  for  related  clinical  conditions.  For 
example, haplotype-based computational genetic analysis 
has identified causative genetic factors affecting analgesic 
medication  [11]  and  inflammatory  pain  responses 
[12,13], and it has identified four genes affecting narcotic 
drug  responses  [11,14-16]  in  mice.  The  latter  genetic 
discovery  generated  a  new  treatment  strategy  for 
preventing  narcotic  drug  withdrawal  symptoms,  which 
was shown to be effective in humans [16]. Moreover, the 
variable  response  to  multiple  classes  of  analgesic 
medications among inbred mouse strains was shown to 
be due to genetic variation within a genetic locus (Kcnj9) 
that  also  encodes  a  potassium  channel  (GIRK3)  [11]. 
Hopefully, characterizing the functional role of KCNS1 in 
neuronal responses and pain perception, and the impact 
of the allelic differences, could lead to new approaches 
for treatment of chronic pain. Although the tractability of 
KCNS1 (or other potassium channels) as a therapeutic 
target  remains  to  be  determined,  small  molecules 
targeting  potassium  channels  have  been  produced 
(reviewed in [17]), and one has attenuated neuropathic 
pain in animal models [18].
Although the KCNS1 Val allele explains only a small 
percentage  of  the  total  variance  (4.6  to  7.8%)  in  the 
chronic  pain  endpoints  in  the  cohorts  studied  [1],  the 
identification of an initial genetic factor for chronic pain 
is  an  important  achievement  for  two  reasons.  First,  it 
shows  that  genetic  factors  can  be  identified  for  this 
condition,  and  this  study  provides  a  template  for 
subsequent  studies.  Second,  it  is  likely  that  a  greater 
percentage of the genetic susceptibility to chronic pain 
can be explained by combining this genetic factor with 
other subsequently identified factors. Moreover, pain is a 
subjective  sensory  symptom;  it  is  difficult  to  measure; 
and  there  are  substantial  psychological  and  emotional 
components  that  contribute  to  the  perception  of  pain 
[19]. It has recently been found that there are different 
subtypes  of  chronic  pain,  which  are  distinct  from  the 
causative  disease  (diabetic  neuropathy,  radicular  back 
pain  and  so  on)  [20].  It  is  likely  that  genetic  factors 
determine whether a chronic pain syndrome will develop 
and the specific subtype that emerges after exposure to a 
triggering  cause.  Thus,  the  impact  of  a  single  genetic 
factor could be much larger if a specific pain subtype is 
examined relative to that measured in a large cohort of 
individuals with different types of chronic pain.
Genomic medicine for chronic pain
Beyond finding new drug targets, identification of genetic 
factors affecting susceptibility to chronic pain syndromes 
could be the lever that drives advances in this difficult 
clinical area. A genetic risk factor could have a substantial 
impact  on  clinical  practice  because  individuals  at 
increased risk for developing a chronic pain syndrome 
could  be  identified  before  a  surgical  procedure  or 
immediately  after  a  traumatic  incident.  The  genetic 
information could be used to develop proactive methods 
for  prevention  of  chronic  pain  syndromes,  enabling 
interventions  to  be  targeted  to  the  high-risk  subset. 
Because  of  the  great  inter-individual  variation  in  the 
response  to  painful  stimuli  and  to  analgesic  drugs, 
knowledge  of  genetic  risk  factors  could  enable  better 
stratification  of  chronic  pain  patients  or  aid  in  the 
selection of the appropriate therapy. Rather than focusing 
on  the  disease  that  is  etiologically  associated  with  the 
chronic  pain,  genetic  stratification  would  enable 
mechanism-based treatment selection.
The Costigan et al. study [1] is hopefully one of the first 
of  many  subsequent  genetic  studies  that  could  lead  to 
entirely new ways to approach chronic pain syndromes. 
Clearly,  the  clinical  and  research  communities  have  a 
long way to go before genetically targeted therapies for 
chronic pain become a reality. However, KCNS1 (or other 
channels)  could  perhaps  become  the  next  target  for  a 
new class of analgesics that are selectively used in the 
20% of the population that are homozygous for the Val 
alleles of KCNS1. The day might soon come when we no 
longer think of ‘chronic pain’ as a single clinical entity, 
but  have  the  tools  to  characterize  the  specific 
‘channelopathy’  that  underlies  the  clinical  presentation 
and targeted treatments for each subgroup.
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